Anti-NKG2A antibody for leukemia or MDS after half-matched transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug that targets NKG2A, a protein that may help prevent cancer cells from hiding from the immune system. It is for people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related conditions who have already received a half-matched stem cell transplant (haploidentical transplant) with a specific anti-rejection drug plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or a related bone marrow disorder.
- You have already received a half-matched stem cell transplant (haploidentical transplant) with a specific anti-rejection drug regimen that includes cyclophosphamide, cyclosporine, and mycophenolate.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study, and you agree to use effective birth control if needed.
- You do not have an active uncontrolled infection or cancer that has spread to your brain or spinal cord.
- Your overall health and organ function are good enough for the transplant (for example, kidneys, lungs, and heart working well enough).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using natural killer (NK) cells combined with antibodies to fight a type of blood cancer called acute myeloid leukemia (AML). It is for people whose AML has come back or not improved with standard treatments.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
This study tests whether adding natural killer (NK) cell infusions to standard consolidation chemotherapy helps keep acute myeloid leukemia (AML) in remission. It's for people with AML who are already in remission after their first treatment.
This trial tests a new type of cell therapy called NKG2D CAR-T for people with AML that has not responded to standard treatment or has come back. It aims to use your own immune cells, modified to attack the leukemia, to help you achieve remission.
This trial tests a new type of immunotherapy using special immune cells (NK cells) that target the CD123 marker found on AML cells. It may help people whose AML has not responded to standard treatments and who have a healthy donor available.
Hear when a new MDS (Myelodysplastic Syndrome) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.